$400B AstraZeneca-Bristol Myers Squibb rumor draws market reaction

Conflicting reports about a potential $400 billion merger between pharma giants AstraZeneca and Bristol Myers Squibb jolted both stocks this week.

Driving the news: The Financial Times reported Sunday that AstraZeneca held talks with BMY about a potential merger, which would have created one of the largest pharmaceutical mergers in history.